A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia
about
Inhibition of DNA-dependent protein kinase catalytic subunit by small molecule inhibitor NU7026 sensitizes human leukemic K562 cells to benzene metabolite-induced apoptosisDNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survivalTargeting DNA topoisomerase II in cancer chemotherapyCharacterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cellsCollision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' AdductsDNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingPreventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer TherapyRole of DNA-dependent protein kinase catalytic subunit in cancer development and treatmentRepair at single targeted DNA double-strand breaks in pluripotent and differentiated human cellsChemical Inhibitors of Non-Homologous End Joining Increase Targeted Construct Integration in Cryptococcus neoformansInhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation responseCohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatinBcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathwayRadiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo.Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cellsNew molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cellsInhibition of homologous recombination by variants of the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs)Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization.Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia.Targeting DNA-PKcs and telomerase in brain tumour cells.Hyperactivation of PARP triggers nonhomologous end-joining in repair-deficient mouse fibroblasts.Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 proteinThe heterogenic final cell cycle of chicken retinal Lim1 horizontal cells is not regulated by the DNA damage response pathway53BP1 mediates the fusion of mammalian telomeres rendered dysfunctional by DNA-PKcs loss or inhibition.SV40 utilizes ATM kinase activity to prevent non-homologous end joining of broken viral DNA replication productsMechanism of heat stress-induced cellular senescence elucidates the exclusive vulnerability of early S-phase cells to mild genotoxic stress.Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joiningModel for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitorNanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema.Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KMRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA.Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.Therapeutic potential of drugs to modulate DNA repair in cancer.
P2860
Q23913433-64F5000B-A04D-43FE-87AE-B29E20D3CB7EQ24316008-E11DC8D6-E9AE-4989-8120-BC7511931DA2Q24649711-F0030D5E-09E2-4CF1-B1DC-0515D1993905Q24808909-145A818E-BE90-411A-B35E-AC481FB3093CQ26744712-99CA6CC3-D9F5-4CB5-B348-E1858D2EFBA0Q26768679-F15A8405-29C0-4A82-B4D8-C4527936AADEQ26776513-5389F0D3-D4EB-4F48-960B-1B51F5EE51FAQ26863501-B7ECDD40-314C-4DF1-B96B-BF580C75A447Q28084568-351054FC-EF03-4978-A57A-84609111ED79Q28274124-3FB3D201-29BA-4C7D-9579-967867367BD3Q28478289-C4940249-755B-4934-A088-B2B13A4F1BA6Q28554238-CA19BFFD-50FD-41C4-8218-DCFB8413FFB3Q28728326-A0CC3E13-B346-4F6E-9B9F-DACBCEA3B731Q30882231-DC9F4A93-0076-4019-B9C4-E0DF551FD238Q33589397-CB45EEE8-DB62-4418-A5F1-FE19111F446BQ33655527-C16DF23E-8183-45BE-83AA-76715EA166B7Q33658587-CCDB1785-854C-4DA3-8208-DB8C20A668FBQ33794733-DF0BB2A7-53CA-486E-9D3E-449F4D57E64DQ33818265-6F0CF7B4-EB6A-4370-BE5D-858606F56762Q34071842-573EF95C-18B1-4F1E-958D-3C29754A6855Q34138796-33ECC984-4E69-4CCE-92C7-B8188F8C9C3DQ34240365-A3B50EAF-6A69-4782-BE51-0628066074FEQ34348888-012423F3-85D1-4F52-8496-42E9E985B916Q34358853-1E264A8B-BF99-490D-A291-7CDD775F11BCQ34423137-5DA6A03B-021D-423A-90C8-D78AE905D3FDQ34474381-13F0AD39-9447-49B0-89E0-FEA8C24305E9Q34583585-511D2A8A-C927-4D9B-8475-3B48C2D826D8Q35046038-6489F0AA-28DD-432B-9DB4-E40E9D917175Q35283684-40BD6FC3-484C-484B-9E9D-130EE6298700Q35490135-667A0DC4-62DD-4186-AC3B-DA29EB2101AAQ35885916-354510BB-027E-4603-9812-2F9B82889AAFQ36028930-9E1BC4F9-1FB7-4012-814A-13C5F5A47E53Q36058572-FDCCE31B-4109-4CB8-BCAA-4BB2A282382FQ36061440-B434974D-7B57-4865-AA44-D4477B74C67DQ36126134-22E9AD95-0F6A-4455-A351-025E54FFFF3FQ36182550-E250BB07-E020-4D13-BC16-5FAC84E7888BQ36193197-EDFDA5E8-B998-41F2-8612-62F34F77FD84Q36425680-01ADBBAB-DEEA-4FE6-B227-62B4E34B751CQ36545168-A92A1B1A-4791-49B8-AAA4-F63F71302072Q36822443-3D580CC6-D59E-495F-B6DB-6104B5DFA1D3
P2860
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A novel DNA-dependent protein ...... d in the treatment of leukemia
@ast
A novel DNA-dependent protein ...... d in the treatment of leukemia
@en
A novel DNA-dependent protein ...... d in the treatment of leukemia
@nl
type
label
A novel DNA-dependent protein ...... d in the treatment of leukemia
@ast
A novel DNA-dependent protein ...... d in the treatment of leukemia
@en
A novel DNA-dependent protein ...... d in the treatment of leukemia
@nl
prefLabel
A novel DNA-dependent protein ...... d in the treatment of leukemia
@ast
A novel DNA-dependent protein ...... d in the treatment of leukemia
@en
A novel DNA-dependent protein ...... d in the treatment of leukemia
@nl
P2093
P921
P3181
P1433
P1476
A novel DNA-dependent protein ...... d in the treatment of leukemia
@en
P2093
Barbara W Durkacz
Caroline A Austin
Elaine Willmore
Graham H Jackson
Michael J Tilby
Nicola J Sunter
Sarah de Caux
P304
P3181
P356
10.1182/BLOOD-2003-07-2527
P407
P577
2004-06-15T00:00:00Z